Metabotropic Glutamate Receptors in Central Nervous System Diseases

Title:Metabotropic Glutamate Receptors in Central Nervous System Diseases

Volume: 17 Issue: 5

Author(s): Anna V. Golubeva, Rachel D. Moloney, Richard M. O’Connor, Timothy G. Dinan and John F. Cryan

Affiliation:

关键词: 自闭症，脆性X综合症，精神障碍，代谢型谷氨酸受体，神经退行性疾病，疼痛。

摘要: Extensive research over the past thirty years has demonstrated a vital role for metabotropic glutamate (mGlu) receptors in the major functions of the central nervous system (CNS). A wealth of preclinical studies provide evidence that pharmacological targeting of mGlu receptors can effectively attenuate the development of symptoms and progression of many CNS disorders in animal models. In this review we summarize the current knowledge on the involvement of mGlu receptors in the pathophysiology of neuropsychiatric disorders (schizophrenia, depression, anxiety and cognitive disorders, pain perception and addiction), as well as neurodegenerative (Alzheimer’s, Huntington’s and Parkinson’s diseases) and neurodevelopmental (fragile X syndrome and autism spectrum disorders) diseases. We further emphasize the therapeutic potential of mGlu receptors’ pharmacological modulators in these diseases, describe the results of clinical trials with these compounds and discuss the potential sources of translational difficulties.

Cite this article as:

Anna V. Golubeva, Rachel D. Moloney, Richard M. O’Connor, Timothy G. Dinan and John F. Cryan , Metabotropic Glutamate Receptors in Central Nervous System Diseases, Current Drug Targets 2016; 17 (5) . https://dx.doi.org/10.2174/1389450116666150316224011